Study on the protective effect of Shengmai San on the myocardium in the type 2 diabetic cardiomyopathy model rat

Journal of Traditional Chinese Medicine

Volumn 31, Issue 3, 2011, Pages 209-219

  Ni, Qing ^a   Wang, Jie ^a   Li, En Qing ^b   Zhao, An Bin ^b   Yu, Bin ^b   Wang, Min ^b   Huang, Chun Rong ^b  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

Apoptosis; Chymase; Collagen fiber; Diabetic cardiomyopathy; Shengmai San; TGF 1; TRB 3; TSP 1

Indexed keywords

BINDING PROTEIN; CARDIOVASCULAR AGENT; CHINESE DRUG; CHYMASE; GLUCOSE; MESSENGER RNA; PROTEIN TRB 3; SHENGMAI SAN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DRUG EFFECT; ELECTROCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; HEART MUSCLE CELL; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

EID: 80053463382     PISSN: 02552922     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0254-6272(11)60044-7     Document Type: Article

References (21)

1. Rullber S, Dulgush J, Yuceogl YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595-602.
2. Hamby RI. Diabetic cardiomyopathy. JAMA 1974; 229: 17492-17493.
3. Paul Poirier, MD, FRCPC, Peter Bogaty. Diastolic Dysfunction in Normotensive Men with Well-Controlled Type 2 Diabetes: Importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care January 2001; 24: 5-10.
4. Schannwell CM. Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomypathy. Cardiology 2002; 98: 33-30.
5. MIzushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000; 101: 899-907.
6. Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006; 47: 693-700. (Pubitemid 43243087)
7. Cai L, Wang Y, Zhou G, Chen T, Song Y, Li X, et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic. Cardiol 2006; 48: 1688-1697. (Pubitemid 44528172)
8. Martin J, Kelly DJ, Mifsud SA, Zhang Y, Cox AJ, See F, et al. Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta. Cardiovasc Res 2005; 65: 694-701. (Pubitemid 40138990)
9. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular: an update. Hypertension 2001; 37: 1053-1059.
10. Liao ZY, Jiang JL, Liu H. Effects of Shengmai San on experimental hyperlipidemia, hemorheology and antioxidation in rats. Liaoning. J Tradit Chin Med (Chin) 2007; 34: 1478-1479.
11. Morishima Y, Nomura A, Uchida Y. Triggering the induction of myofibroblast and fibrogenesis by airway epithelial shedding. Am J Respir Cell Mol Biol 2001; 24: 1-11. (Pubitemid 32097502)
12. Zhong M, Zhang W, Miao Y, Ma X, Gong HP, Sun H, et al. The role of glucose / TSP-1 / TGFβ1 signal pathways in diabetic cardiomyopathy. Chin J Cardio (Chin) 2006; 34: 217-220.
13. Kiss-toth E, Bagstaff SM, Sung HY, Jozsa V, Dempsey C, Caunt JC, et al. Human Tribbles, a Protein family controlling mitogen-activated Protein kinase cascades. J Biol Chem 2004; 279: 42703-42708. (Pubitemid 39372156)
14. Sung H.Y., Francis S.E., Crossman D.C., Kiss-Toth E. Regulation of expression and signaling modulator function of mammalian tribbles is cell-type specific. Immunllogy Letters 2006; 104: 171-177. (Pubitemid 43330724)
15. Stmiskova M, Baraneik M, Neekar J. Mitogen-activated Protein kinases in the acutediabe-tiemyocardium. Mol Cell Bioehem 2003; 249: 59-65.
16. Purves T, Middlemas A, Agthong S. A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. The FASEB J 2001; 15: 2508-2514. (Pubitemid 33063180)
17. Ling L, Sawamura Tatsuya, RENIER Geneviève. Glucose enhances human macrophage LOX-1 expression: Role for LOX-1 in glucose-induced macrophage foam cell formation. Cire Res 2004; 94: 892-890.
18. Park JK, Fischer R, Dechend R, et al. P38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage. Hypertension 2007; 49: 481-489.
19. Saka Masako, Obata Koji, Ichihara Sahoko, et al. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: Potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway. Clin Exp Pharmacol Physiol 2006; 33: 1164-1171.
20. Cong L, Yu MH, Li YM. Chymase and diabetic cardiomyopathy. Foreign Medicine. Endocrinology (Chin). 2004; 24: 33-35.
21. Zhao XY, Zhao LY, Zheng QS, He YP, Lu XL. Effects of Chymase on cardiac fibroblast proliferation and collagen synthesis. Heart (Chin) 2008; 20: 268-272.